Stefani Corsi-Travali

974 total citations
5 papers, 285 citations indexed

About

Stefani Corsi-Travali is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stefani Corsi-Travali has authored 5 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 2 papers in Molecular Biology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stefani Corsi-Travali's work include Peptidase Inhibition and Analysis (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Ubiquitin and proteasome pathways (2 papers). Stefani Corsi-Travali is often cited by papers focused on Peptidase Inhibition and Analysis (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Ubiquitin and proteasome pathways (2 papers). Stefani Corsi-Travali collaborates with scholars based in United States and United Kingdom. Stefani Corsi-Travali's co-authors include Soheila Najafzadeh, Daniele Piomelli, S. Henry, Marc D. Normandin, M. Zheng, Yiyun Huang, Richard E. Carson, Robert H. Pietrzak, Jim Ropchan and Marc N. Potenza and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Molecular Psychiatry.

In The Last Decade

Stefani Corsi-Travali

5 papers receiving 280 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefani Corsi-Travali United States 4 200 116 62 51 37 5 285
Lalita Shrestha United States 4 203 1.0× 145 1.3× 56 0.9× 72 1.4× 14 0.4× 5 328
M. Zheng United States 5 221 1.1× 176 1.5× 86 1.4× 57 1.1× 38 1.0× 8 393
Ashleigh L. Osborne Australia 7 231 1.2× 124 1.1× 69 1.1× 29 0.6× 12 0.3× 8 361
Gilava Hamuni Germany 5 130 0.7× 57 0.5× 71 1.1× 62 1.2× 69 1.9× 5 328
Juliane K. Mueller Germany 10 226 1.1× 126 1.1× 53 0.9× 20 0.4× 39 1.1× 14 391
Stephen Ra United States 3 159 0.8× 160 1.4× 68 1.1× 29 0.6× 19 0.5× 3 315
Tibor Štark Czechia 12 194 1.0× 118 1.0× 36 0.6× 29 0.6× 32 0.9× 20 404
Julia Morath Germany 5 125 0.6× 56 0.5× 32 0.5× 73 1.4× 69 1.9× 5 307
Janelle M. Lugo United States 8 149 0.7× 128 1.1× 26 0.4× 30 0.6× 14 0.4× 8 279
Cristiano Chaves Brazil 8 109 0.5× 77 0.7× 38 0.6× 25 0.5× 22 0.6× 19 273

Countries citing papers authored by Stefani Corsi-Travali

Since Specialization
Citations

This map shows the geographic impact of Stefani Corsi-Travali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefani Corsi-Travali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefani Corsi-Travali more than expected).

Fields of papers citing papers by Stefani Corsi-Travali

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefani Corsi-Travali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefani Corsi-Travali. The network helps show where Stefani Corsi-Travali may publish in the future.

Co-authorship network of co-authors of Stefani Corsi-Travali

This figure shows the co-authorship network connecting the top 25 collaborators of Stefani Corsi-Travali. A scholar is included among the top collaborators of Stefani Corsi-Travali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefani Corsi-Travali. Stefani Corsi-Travali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

5 of 5 papers shown
1.
Aggarwal, Rahul, Dan Costin, Vincent O’Neill, et al.. (2020). Phase 1b study of BXCL701, a novel small molecule inhibitor of dipeptidyl peptidases (DPP), combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). e17581–e17581. 6 indexed citations
2.
Aggarwal, Rahul, Dan Costin, Jingsong Zhang, et al.. (2020). 341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC). SHILAP Revista de lepidopterología. A208–A209. 3 indexed citations
3.
Farago, Anna F., Shivaani Kummar, Stefani Corsi-Travali, et al.. (2018). P1.13-40 Rapid, Robust and Durable Responses to Larotrectinib in Patients with TRK Fusion Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S597–S598. 5 indexed citations
4.
Velcheti, Vamsidhar, Todd M. Bauer, Vivek Subbiah, et al.. (2017). OA 12.07 LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases. Journal of Thoracic Oncology. 12(11). S1778–S1778. 10 indexed citations
5.
Normandin, Marc D., Robert H. Pietrzak, Daniele Piomelli, et al.. (2013). Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Molecular Psychiatry. 18(9). 1034–1040. 261 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026